Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

• Yuliya Lytvyn, PhD,
• Asfandyar Mufti, MD,
• Hiba Zaaroura, MD,
• Muskaan Sachdeva, BHSc,
• Justin D. Lu, MSc,
• Brian D. Rankin, PhD,
• Vimal H. Prajapati, MD,
• Ronald Vender, MD,
• Jensen Yeung, MD, FRCPC

Affiliations

Yuliya Lytvyn, PhD

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Asfandyar Mufti, MD

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Hiba Zaaroura, MD

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Muskaan Sachdeva, BHSc

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Justin D. Lu, MSc

Michael G. DeGroote School of Medicine, Faculty of Medicine, Hamilton, Ontario, Canada

Brian D. Rankin, PhD

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Vimal H. Prajapati, MD

Division of Dermatology, Department of Medicine, and Divisions of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; and Probity Medical Research, Calgary, Alberta, Canada

Ronald Vender, MD

Dermatrials Research Inc., Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Jensen Yeung, MD, FRCPC

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Probity Medical Research Inc., Waterloo, Ontario, Canada; Correspondence to: Jensen Yeung, MD, FRCPC, Department of Dermatology, Women's College Hospital, 76 Grenville St, Fifth Floor, Toronto, Ontario M5S 1B2, Canada